CareDx Inc. reported first‑quarter 2026 revenue of $118 million, a 39% year‑over‑year increase that exceeded analyst expectations. Non‑GAAP earnings per share were $0.34, beating the consensus estimate of –$0.06 by $0.40 and surpassing the GAAP EPS of $0.05. The strong earnings beat was driven by higher testing‑services volume, improved pricing, and disciplined cost control that lifted the non‑GAAP gross margin to 73%.
The company’s testing‑services segment generated $91 million, while patient and digital‑solutions revenue rose to $16 million, reflecting continued demand for its transplant‑focused diagnostics and software platform. Gross margin expansion was largely a result of a favorable mix shift toward higher‑margin services and effective supply‑chain management, offsetting modest cost inflation in raw materials and labor.
CareDx posted GAAP net income of $3 million, reversing the $21.4 million net loss reported in the prior year. Adjusted EBITDA reached $19 million, up from $5 million in Q1 2025, thanks to a $14 million gain from prior‑period collections that increased revenue per test. The collections gain, while boosting top‑line numbers, also highlights the company’s aggressive revenue‑cycle management.
Management raised full‑year revenue guidance to $447 million–$465 million, up from the previous $420 million–$444 million range, and reaffirmed an adjusted EBITDA margin target of 8.3%. The guidance lift signals confidence in sustained demand for its core diagnostics and the anticipated impact of the upcoming AlloHeme launch. The company also announced the divestiture of its lab‑products business for approximately $170 million, the acquisition of Naveris for $160 million upfront plus milestones, and a new $100 million share‑repurchase program, underscoring a focus on core competencies and shareholder returns. A potential litigation overhang with Natera could result in a loss of up to $96.3 million, adding a risk element to the outlook.
Investors reacted with a muted market response, partly due to profit‑taking after a recent rally and concerns about the quality of the prior‑period collections that inflated revenue per test. Analysts noted that while the earnings beat and guidance raise are encouraging, the company’s reliance on out‑of‑period collections and the looming LCD risk could temper enthusiasm. Nonetheless, the strong operational turnaround and strategic portfolio reshaping position CareDx for continued growth in the transplant diagnostics and emerging oncology MRD markets.
Overall, CareDx’s Q1 2026 results demonstrate a robust recovery, with revenue growth, margin expansion, and a positive outlook that reflects both operational execution and strategic focus on high‑growth segments. The company’s ability to convert volume gains into profitability, coupled with its portfolio realignment, suggests a solid trajectory for the remainder of 2026 and beyond.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.